Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
R-Pharm
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06320353CT.gov Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | — | Unknown | — | — | — |
NCT06307093CT.gov Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rph-075 (this asset) | R-Pharm | P3 | BB · 66 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Mart-1 Antigen | Mayo Clinic | P2 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Rph-075
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P1 | CC · 43 |
| Head And Neck Squamous Cell Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rph-075 in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rph-075-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →